{"DataElement":{"publicId":"2798046","version":"2","preferredName":"Begin Or Continue Chronic Graft Versus Host Disease Occurrence Status Indicator","preferredDefinition":"The indicator that describes if chronic graft versus host disease began or continued.","longName":"2798044v1.0:2787864v1.5","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2798044","version":"1","preferredName":"Begin Or Continue Chronic Graft Versus Host Disease Occurrence","preferredDefinition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation._An instance of something happening, such as an event or incident","longName":"2798042v1.0:2234856v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2798042","version":"1","preferredName":"Begin Or Continue Chronic Graft Versus Host Disease","preferredDefinition":"Have a beginning, in a temporal, spatial, or evaluative sense.:Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Existing in time or space without stop or interruption.:A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation.","longName":"C25431:C37998:C53279:C4981","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Continue","conceptCode":"C53279","definition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B09AF0E-FC3C-601E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-06","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-06","modifiedBy":"ONEDATA","dateModified":"2008-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234856","version":"1","preferredName":"Occurrence","preferredDefinition":"Occurrence; an instance of something happening.","longName":"C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-72B8-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B09AF0E-FC4A-601E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-06","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2787864","version":"1.5","preferredName":"Graft Versus Host Disease Status Indicator","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._A condition or state at a particular time._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"2787864v1.5","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Progressed to chronic GVHD","valueDescription":"Progressive Chronic Graft Versus Host Disease","ValueMeaning":{"publicId":"2787865","version":"1","preferredName":"Progressive Chronic Graft Versus Host Disease","longName":"2787865","preferredDefinition":"Advancing in extent or severity.: A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive","conceptCode":"C25254","definition":"Advancing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57BEB4B1-FA3C-4A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E4F5C02-DFF6-74FB-E050-BB89AD436FB2","beginDate":"2008-09-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"ONEDATA","dateModified":"2015-08-27","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E4F5C02-E000-74FB-E050-BB89AD436FB2","beginDate":"2008-09-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"ONEDATA","dateModified":"2015-08-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E4F5C02-E00A-74FB-E050-BB89AD436FB2","beginDate":"2008-09-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"ONEDATA","dateModified":"2015-08-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E4F5C02-E014-74FB-E050-BB89AD436FB2","beginDate":"2008-09-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"ONEDATA","dateModified":"2015-08-27","deletedIndicator":"No"},{"value":"No symptoms, but recipient is receiving treatment","valueDescription":"Current Therapy Negation Symptom","ValueMeaning":{"publicId":"3036770","version":"1","preferredName":"Current Therapy Negation Symptom","longName":"3036770","preferredDefinition":"Occurring in or belonging to the present time.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: An operation in which a term denies or inverts the meaning of another term or construction.: An indication that a person has a condition or disease.  Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Symptom","conceptCode":"C4876","definition":"Subjective evidence of disease perceived by the patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"831F33E4-528B-1721-E040-BB89AD435762","latestVersionIndicator":"Yes","beginDate":"2010-03-31","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E4F5C02-E01E-74FB-E050-BB89AD436FB2","beginDate":"2010-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"ONEDATA","dateModified":"2015-08-27","deletedIndicator":"No"},{"value":"Acute GVHD persists from prior HCT / DCI","valueDescription":"Acute Graft Versus Host Disease Persistent Prior Hematopoietic Stem Cell Transplantation And/Or Donor Cellular Infusion","ValueMeaning":{"publicId":"4987181","version":"1","preferredName":"Acute Graft Versus Host Disease Persistent Prior Hematopoietic Stem Cell Transplantation And/Or Donor Cellular Infusion","longName":"4987181","preferredDefinition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.: Retained; never-ceasing.: Earlier in time or order.: Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.): Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.: Used to indicate that either or both of two items or options may be valid.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Persistent","conceptCode":"C43623","definition":"Retained; never-ceasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Hematopoietic Stem Cell","conceptCode":"C12551","definition":"Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E4F5C02-E092-74FB-E050-BB89AD436FB2","latestVersionIndicator":"Yes","beginDate":"2015-08-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E4F5C02-E0AB-74FB-E050-BB89AD436FB2","beginDate":"2015-08-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"ONEDATA","dateModified":"2015-08-27","deletedIndicator":"No"},{"value":"Chronic GVHD persists from prior HCT / DCI","valueDescription":"Chronic Graft Versus Host Disease Persistent Prior Hematopoietic Stem Cell Transplantation And/Or Donor Cellular Infusion","ValueMeaning":{"publicId":"4987180","version":"1","preferredName":"Chronic Graft Versus Host Disease Persistent Prior Hematopoietic Stem Cell Transplantation And/Or Donor Cellular Infusion","longName":"4987180","preferredDefinition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.: Retained; never-ceasing.: Earlier in time or order.: Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.): Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.: Used to indicate that either or both of two items or options may be valid.: A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Persistent","conceptCode":"C43623","definition":"Retained; never-ceasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Hematopoietic Stem Cell","conceptCode":"C12551","definition":"Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E4F5C02-E067-74FB-E050-BB89AD436FB2","latestVersionIndicator":"Yes","beginDate":"2015-08-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E4F5C02-E080-74FB-E050-BB89AD436FB2","beginDate":"2015-08-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"ONEDATA","dateModified":"2015-08-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2787863","version":"1","preferredName":"Graft Versus Host Disease Status Indicator","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:A condition or state at a particular time.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C3063:C25688:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57BEB4B1-FA12-4A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-09-25","modifiedBy":"ONEDATA","dateModified":"2008-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E4F5C02-DFDF-74FB-E050-BB89AD436FB2","latestVersionIndicator":"Yes","beginDate":"2015-08-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"KUMMEROA","dateModified":"2021-02-23","changeDescription":". 2021-2-23 ak Ok to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964922","version":"1","longName":"2200r1: 6 Month to 2 Year Post-HSCT Data","context":"NHLBI"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Did chronic GVHD develop or p","type":"Preferred Question Text","description":"Did chronic GVHD develop or persist?","url":null,"context":"NHLBI"},{"name":"Did chronic GVHD develop or persist?","type":"Application Standard Question Text","description":"Did chronic GVHD develop or persist?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E4F9FB4-BB41-B70B-E050-BB89AD435424","latestVersionIndicator":"Yes","beginDate":"2015-08-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-27","modifiedBy":"KUMMEROA","dateModified":"2021-02-23","changeDescription":".-2021-2-23 ak OK to release per WZ. System generated def displayed as alt def. AK 8/27/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}